{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:16:03Z","timestamp":1794492963047,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T00:00:00Z","timestamp":1289952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1756-9966-29-149","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T07:14:04Z","timestamp":1289978044000},"source":"Crossref","is-referenced-by-count":39,"title":["Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line"],"prefix":"10.1186","volume":"29","author":[{"given":"Yasumichi","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachio","family":"Fushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunobu","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itasu","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,17]]},"reference":[{"key":"396_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3322\/canjclin.55.6.334","volume":"55","author":"RF Souza","year":"2005","unstructured":"Souza RF, Spechler SJ: Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA cancer J Clin. 2005, 55: 334-51.","journal-title":"CA cancer J Clin"},{"key":"396_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00595-008-3860-1","volume":"39","author":"M Ikeguchi","year":"2009","unstructured":"Ikeguchi M, Miyake T, Matsunaga T, et al: Recent results of therapy for scirrhous gastric cancer. Surg Today. 2009, 39: 290-4.","journal-title":"Surg Today"},{"key":"396_CR3","first-page":"874","volume":"49","author":"CY Chen","year":"2002","unstructured":"Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH: Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002, 49: 874-7.","journal-title":"Hepatogastroenterology"},{"key":"396_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, et al: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010, 21: 67-70.","journal-title":"Ann Oncol"},{"key":"396_CR5","first-page":"1305","volume":"19","author":"S Fushida","year":"2008","unstructured":"Fushida S, Kinoshita J, Yagi Y, et al: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008, 19: 1305-10.","journal-title":"Oncol Rep"},{"key":"396_CR6","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1200\/JCO.2006.08.0887","volume":"24","author":"MA Shah","year":"2006","unstructured":"Shah MA, Ramanathan RK, Ilson DH, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006, 24: 5201-6.","journal-title":"J Clin Oncol"},{"key":"396_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/annonc\/mdl459","volume":"18","author":"C Pinto","year":"2007","unstructured":"Pinto C, Di Fabio F, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007, 18: 510-7.","journal-title":"Ann Oncol"},{"key":"396_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/ijc.11679","volume":"109","author":"B Schniewind","year":"2004","unstructured":"Schniewind B, Christgen M, Kurdow R, et al: Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004, 109: 182-8.","journal-title":"Int J Cancer"},{"key":"396_CR9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3748\/wjg.v8.i3.400","volume":"8","author":"JY Fang","year":"2002","unstructured":"Fang JY, Lu YY: Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol. 2002, 8: 400-5.","journal-title":"World J Gastroenterol"},{"key":"396_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Alli's CD: Translating the histone code. Science. 2001, 293: 1074-80.","journal-title":"Science"},{"key":"396_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i3-4.70","volume":"10","author":"JR Davie","year":"2000","unstructured":"Davie JR, Moniwa M: Control of chromatin remodeling. Crit Rev Eukaryotic Gene Expression. 2000, 10: 303-25.","journal-title":"Crit Rev Eukaryotic Gene Expression"},{"key":"396_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1074-5521(02)00092-3","volume":"9","author":"CM Grozinger","year":"2002","unstructured":"Grozinger CM, Schreiber SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002, 9: 3-16.","journal-title":"Chem Biol"},{"key":"396_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/excr.2000.5080","volume":"262","author":"SG Gray","year":"2001","unstructured":"Gray SG, Ekstr\u00f6m TJ: The human histone deacetylase family. Exp Cell Res. 2001, 262: 75-83.","journal-title":"Exp Cell Res"},{"key":"396_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2004.10.001","volume":"40","author":"C Monneret","year":"2005","unstructured":"Monneret C: Histone deacetylase inhibitors. Eur J Med Chem. 2005, 40: 1-13.","journal-title":"Eur J Med Chem"},{"key":"396_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.coph.2006.03.010","volume":"6","author":"N Carey","year":"2006","unstructured":"Carey N, La Thangue NB: Histone deacetylase inhibitors:gathering pace. Curr Opin Pharmacol. 2006, 6: 369-75.","journal-title":"Curr Opin Pharmacol"},{"key":"396_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9","volume":"88","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Yokozaki H, Kuniyasu H, et al: Effect of Trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer. 2000, 88: 992-7.","journal-title":"Int J Cancer"},{"key":"396_CR17","first-page":"563","volume":"16","author":"X Zhang","year":"2006","unstructured":"Zhang X, Yashiro M, Ren J, et al: Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep. 2006, 16: 563-8.","journal-title":"Oncol Rep"},{"key":"396_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jb\/mvn074","volume":"144","author":"S Sami","year":"2008","unstructured":"Sami S, H\u00f6ti N, Xu HM, Shen Z, Huang X: Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem. 2008, 144: 357-62.","journal-title":"J Biochem"},{"key":"396_CR19","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","volume":"22","author":"OH Kramer","year":"2003","unstructured":"Kramer OH, Zhu P, Ostendorff HP, et al: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22: 3411-20.","journal-title":"EMBO J"},{"key":"396_CR20","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20: 6969-78.","journal-title":"EMBO J"},{"key":"396_CR21","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","volume":"5","author":"A Hrzenjak","year":"2006","unstructured":"Hrzenjak A, Moinfar F, Kremser ML, et al: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 2006, 5: 2203-10.","journal-title":"Mol Cancer Ther"},{"key":"396_CR22","first-page":"1139","volume":"13","author":"P Rocchi","year":"2005","unstructured":"Rocchi P, Tonelli R, Camerin C, et al: p21Waf1\/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005, 13: 1139-44,.","journal-title":"Oncol Rep"},{"key":"396_CR23","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.2174\/092986707782023299","volume":"14","author":"N Takai","year":"2007","unstructured":"Takai N, Narahara H: Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem. 2007, 14: 2548-53.","journal-title":"Curr Med Chem"},{"key":"396_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/jnci\/94.7.504","volume":"94","author":"X Yu","year":"2002","unstructured":"Yu X, Guo ZS, Marcu MG, et al: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002, 94: 504-13.","journal-title":"J Natl Cancer Inst"},{"key":"396_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4161\/cbt.1.1.38","volume":"1","author":"MV Blagosklonny","year":"2002","unstructured":"Blagosklonny MV, Robey R, Sackett DL, et al: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002, 1: 37-41.","journal-title":"Mol Cancer Ther"},{"key":"396_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1677\/ERC-07-0096","volume":"14","author":"MG Catalano","year":"2007","unstructured":"Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G: Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer. 2007, 14: 839-45.","journal-title":"Endocr Relat Cancer"},{"key":"396_CR27","doi-asserted-by":"crossref","unstructured":"Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet. 344: 1267-72.","DOI":"10.1016\/S0140-6736(94)90754-4"},{"key":"396_CR28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001, 19: 1001-7.","journal-title":"J Clin Oncol"},{"key":"396_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","volume":"64","author":"N Gurvich","year":"2004","unstructured":"Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004, 64: 1079-86.","journal-title":"Cancer Res"},{"key":"396_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev.pharmtox.39.1.295","volume":"39","author":"DG Johnson","year":"1999","unstructured":"Johnson DG, Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999, 39: 295-312.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"396_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ijc.20842","volume":"115","author":"J Joseph","year":"2005","unstructured":"Joseph J, Wajapeyee N, Somasundaram K: Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int J Cancer. 2005, 115: 11-8.","journal-title":"Int J Cancer"},{"key":"396_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4161\/cbt.317","volume":"1","author":"M Kitazono","year":"2002","unstructured":"Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV: The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol Ther. 2002, 1: 665-8.","journal-title":"Cancer Biol Ther"},{"key":"396_CR33","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8+<1668::AID-CNCR13>3.0.CO;2-W","volume":"77","author":"M Yashiro","year":"1996","unstructured":"Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as 'soil' for peritoneal dissemination. Cancer. 1996, 77: 1668-75.","journal-title":"Cancer"},{"key":"396_CR34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/sj.bjc.6605561","volume":"102","author":"O Shinto","year":"2010","unstructured":"Shinto O, Yashiro M, Kawajiri H, et al: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer. 2010, 102: 844-51.","journal-title":"Br J Cancer"},{"key":"396_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1159\/000011916","volume":"55","author":"S Kinugasa","year":"1998","unstructured":"Kinugasa S, Abe S, Tachibana M, et al: Over expression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology. 1998, 55: 582-7.","journal-title":"Oncology"},{"key":"396_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1349-7006.1997.tb00360.x","volume":"88","author":"T Inoue","year":"1997","unstructured":"Inoue T, Chung YS, Yashiro M, et al: Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res. 1997, 88: 152-9.","journal-title":"Jpn J Cancer Res"},{"key":"396_CR37","first-page":"355","volume":"16","author":"T Koyama","year":"2000","unstructured":"Koyama T, Yashiro M, Inoue T, et al: TGF-beta1 secreted by gastric fibroblasts up-regulates CD44 H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol. 2000, 16: 355-62.","journal-title":"Int J Oncol"},{"key":"396_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10911-010-9181-1","volume":"15","author":"MA Taylor","year":"2010","unstructured":"Taylor MA, Parvani JG, Schiemann WP: The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2010, 15: 169-90.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"396_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2183\/pjab.85.314","volume":"85","author":"K Miyazono","year":"2009","unstructured":"Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2009, 85: 314-23.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"396_CR40","first-page":"121","volume":"55","author":"M Gos","year":"2009","unstructured":"Gos M, Mi\u0142oszewska J, Przybyszewska M: Epithelial-mesenchymal transition in cancer progression. Postepy Biochem. 2009, 55: 121-8.","journal-title":"Postepy Biochem"},{"key":"396_CR41","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.bbamcr.2007.05.016","volume":"1773","author":"W Glenisson","year":"2007","unstructured":"Glenisson W, Castronovo V, Waltregny D: Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta. 2007, 1773: 1572-82.","journal-title":"Biochim Biophys Acta"},{"key":"396_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, et al: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008, 409: 581-9.","journal-title":"Biochem J"},{"key":"396_CR43","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","volume":"22","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Li N, Caron C, et al: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22: 1168-79.","journal-title":"EMBO J"},{"key":"396_CR44","first-page":"937","volume":"1","author":"MV Blagosklonny","year":"2002","unstructured":"Blagosklonny MV, Robey R, Sackett DL, et al: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002, 1: 937-41.","journal-title":"Mol Cancer Ther"},{"key":"396_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, et al: HDAC6 is a microtubule-associated deacetylase. Nature. 2002, 417: 455-8.","journal-title":"Nature"},{"key":"396_CR46","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-06-0209","volume":"5","author":"SC Dowdy","year":"2006","unstructured":"Dowdy SC, Jiang S, Zhou XC, et al: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther. 2006, 5: 2767-76.","journal-title":"Mol Cancer Ther"},{"key":"396_CR47","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/labinvest.2009.149","volume":"90","author":"D Zhang","year":"2010","unstructured":"Zhang D, Sun L, Xian W, et al: Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta\/Smad activity. Lab Invest. 2010, 90: 436-47.","journal-title":"Lab Invest"},{"key":"396_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jss.2006.12.558","volume":"141","author":"HS Choi","year":"2007","unstructured":"Choi HS, Savard CE, Choi JW, Kuver R, Lee SP: Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts. J Surg Res. 2007, 141: 183-91.","journal-title":"J Surg Res"},{"key":"396_CR49","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1371\/journal.pmed.0020354","volume":"2","author":"X Liu","year":"2005","unstructured":"Liu X, Zhu S, Wang T, et al: Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med. 2005, 2: e354-","journal-title":"PLoS Med"},{"key":"396_CR50","doi-asserted-by":"publisher","first-page":"L864","DOI":"10.1152\/ajplung.00128.2009","volume":"297","author":"W Guo","year":"2009","unstructured":"Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA: Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol. 2009, 297: L864-70.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"396_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, et al: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007, 97: 177-82.","journal-title":"Br J Cancer"},{"key":"396_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","volume":"100","author":"A Rocca","year":"2009","unstructured":"Rocca A, Minucci S, Tosti G, et al: A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer. 2009, 100: 28-36.","journal-title":"Br J Cancer"},{"key":"396_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0885-3924(00)00266-9","volume":"21","author":"JR Hardy","year":"2001","unstructured":"Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R: A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage. 2001, 21: 204-9.","journal-title":"J Pain Symptom Manage"},{"key":"396_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/156800908784533508","volume":"8","author":"V Rodriguez-Menendez","year":"2008","unstructured":"Rodriguez-Menendez V, Tremolizzo L, Cavaletti G: Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?. Curr Cancer Drug Targets. 2008, 8: 266-74.","journal-title":"Curr Cancer Drug Targets"},{"key":"396_CR55","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","volume":"14","author":"F Braiteh","year":"2008","unstructured":"Braiteh F, Soriano AO, Garcia-Manero G, et al: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008, 14: 6296-301.","journal-title":"Clin Cancer Res"},{"key":"396_CR56","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","volume":"15","author":"P Munster","year":"2009","unstructured":"Munster P, Marchion D, Bicaku E, et al: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC. Clin Cancer Res. 2009, 15: 2488-96.","journal-title":"Clin Cancer Res"},{"key":"396_CR57","first-page":"769","volume":"18","author":"M Nakagawa","year":"2007","unstructured":"Nakagawa M, Oda Y, Eguchi T, et al: Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007, 18: 769-74.","journal-title":"Oncol Rep"},{"key":"396_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","volume":"9","author":"W Weichert","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V, et al: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9: 139-48.","journal-title":"Lancet Oncol"},{"key":"396_CR59","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","volume":"92","author":"JH Choi","year":"2001","unstructured":"Choi JH, Kwon HJ, Yoon BI, et al: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001, 92: 1300-4.","journal-title":"Jpn J Cancer Res"},{"key":"396_CR60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","volume":"113","author":"J Song","year":"2005","unstructured":"Song J, Noh JH, Lee JH, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005, 113: 264-8.","journal-title":"APMIS"},{"key":"396_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","volume":"9","author":"W Weichert","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V, et al: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9: 139-48.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-29-149\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T08:21:30Z","timestamp":1548231690000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-29-149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,17]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-29-149","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,17]]},"article-number":"149"}}